Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.43 |
| ▸ | CTSL | P07711 | 5/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751274 | 0.88 | CTSK (0.50) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6753451 | 0.88 | CDK2 (0.41) | CTSKCTSLCTSSHCKNR2C2 | |
| SCHEMBL6752285 | 0.86 | HPGDS (0.39) | CTSKCTSLCTSSCTSBHCK | |
| SCHEMBL6701942 | 0.84 | CTSK (0.40) | CTSKCTSLCTSSCTSBHSPA5 | |
| SCHEMBL6753487 | 0.79 | CTSL (0.56) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6752300 | 0.79 | CTSK (0.46) | CTSKCTSLCTSSCTSBHCK | |
| SCHEMBL6752379 | 0.76 | HPGDS (0.48) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6751681 | 0.76 | CTSK (0.44) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6751550 | 0.76 | AAK1 (0.43) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6753439 | 0.76 | CTSK (0.48) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1362042-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002057249-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSK 5/4885CTSL 23/4885CTSS 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.